Goldline Pharmaceutical, a company in the Pharmaceuticals industry, reported revenue of ₹15 crore and net profit of ₹2.05 crore for the September 2026 quarter.
Goldline Pharmaceutical (BSE: GLPL) closed at ₹29.00 on 20 Nov 2026. Its market capitalisation is ₹28 crore and it trades at 6.8 times earnings.
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.